ArchPoint Investors’s Iovance Biotherapeutics IOVA Stock Holding History

ArchPoint Investors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-92,500	Closed	-$886K	–	60
2022 Q3	$886K	Sell	92,500 -1,500	-2%	-$17.3K	0.36%	37
2022 Q2	$1.04M	Sell	94,000 -500	-0.5%	-$6.55K	0.41%	33
2022 Q1	$1.57M	Hold	94,500	–	–	0.54%	32
2021 Q4	$1.8M	Hold	94,500	–	–	0.54%	33
2021 Q3	$2.33M	Sell	94,500 -2,944	-3%	-$69.4K	0.7%	25
2021 Q2	$2.54M	Buy	97,444 +25,276	+35%	+$657K	0.86%	24
2021 Q1	$2.29M	Buy	72,168 +3,000	+4%	+$124K	0.65%	26
2020 Q4	$3.21M	Buy	69,168 +57,418	+489%	+$2.28M	0.89%	27
2020 Q3	$387K	Buy	+11,750	New	+$360K	0.12%	71
2019 Q1	–	Sell	-5,000	Closed	-$44K	–	136
2018 Q4	$44K	Buy	+5,000	New	+$48.2K	0.02%	96

Other funds holding IOVA

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ArchPoint Investors's IOVA Position: Q4 2022 in Review

ArchPoint Investors sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 92,500 shares — an estimated $886K sold.

ArchPoint Investors first reported a position in IOVA in Q4 2018 and held it in 10 quarters. The position peaked at $3.21M in Q4 2020. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

ArchPoint Investors reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
ArchPoint Investors sold 92,500 Iovance Biotherapeutics shares in Q4 2022, an estimated $886K.
ArchPoint Investors first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 10 quarters.
ArchPoint Investors's Iovance Biotherapeutics position peaked at $3.21M in Q4 2020.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on ArchPoint Investors's 13F filing for Q4 2022, filed 13 Feb 2023.